Abstract
Established modalities of treatment for obstructive coronary artery disease include medical therapy, bypass surgery and percutaneous coronary intervention. Similarly, conventional treatment of congestive heart failure is also limited to medical therapy, temporary assist devices and transplantation. A significant subset of patients with severe symptomatic coronary artery disease and end stage heart failure is not eligible for these traditional methods of treatment. In spite of maximal medical and revascularization therapy, these patients may not get adequate symptomatic benefit. After a decade of investigations, gene therapy has emerged as a promising therapeutic option for this group of patients. This review discusses newer modalities of therapy for this subset, including therapeutic angiogenesis with growth factors and cell transplantation.
Current Gene Therapy
Title: Gene Therapy in Cardiovascular Diseases
Volume: 2 Issue: 4
Author(s): Kamala P. Tamirisa and Debabrata Mukherjee
Affiliation:
Abstract: Established modalities of treatment for obstructive coronary artery disease include medical therapy, bypass surgery and percutaneous coronary intervention. Similarly, conventional treatment of congestive heart failure is also limited to medical therapy, temporary assist devices and transplantation. A significant subset of patients with severe symptomatic coronary artery disease and end stage heart failure is not eligible for these traditional methods of treatment. In spite of maximal medical and revascularization therapy, these patients may not get adequate symptomatic benefit. After a decade of investigations, gene therapy has emerged as a promising therapeutic option for this group of patients. This review discusses newer modalities of therapy for this subset, including therapeutic angiogenesis with growth factors and cell transplantation.
Export Options
About this article
Cite this article as:
Tamirisa P. Kamala and Mukherjee Debabrata, Gene Therapy in Cardiovascular Diseases, Current Gene Therapy 2002; 2 (4) . https://dx.doi.org/10.2174/1566523023347643
DOI https://dx.doi.org/10.2174/1566523023347643 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Cellular Senescence During Vascular Calcification: A Key Paradigm in Aging Research
Current Aging Science Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant
Mini-Reviews in Medicinal Chemistry Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Estrogen and Cytokines Production - The Possible Cause of Gender Differences in Neurological Diseases
Current Pharmaceutical Design Pulmonary Hypertension and Lung Transplantation
Current Hypertension Reviews CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship?
Current Cardiology Reviews Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Medication Adherence and Associated Factors among Chronic Heart Failure Clients on Follow Up Oromia Region, West Ethiopia
Cardiovascular & Hematological Agents in Medicinal Chemistry Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Cardiovascular & Hematological Disorders-Drug Targets Magnesium Lithospermate B Extracted from Salvia Miltiorrhiza, A Potential Substitute for Cardiac Glycosides
Mini-Reviews in Organic Chemistry Editorial from Guest Editor: Current Management of Sleep Apnea and Comorbidities
Current Respiratory Medicine Reviews Pioglitazone and Rosiglitazone: Effects of Treatment with a Thiazolidinedione on Lipids and Non Conventional Cardiovascular Risk Factors
Current Clinical Pharmacology Regulation of Iron Absorption in Hemoglobinopathies
Current Molecular Medicine NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation Inhibitors in Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design Clinical Implications of Recent Insights into the Structural Biology of Beta2 Adrenoceptors
Current Drug Targets Clozapine Safety, 40 Years Later
Current Drug Safety